Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.56 |
| ▸ | TPMT | P51580 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL870352 | 0.82 | MLYCD (0.57) | MLYCDALDH1A1HPGDSMN1; SMN2GSK3B | |
| SCHEMBL1012521 | 0.82 | MLYCD (0.57) | MLYCDALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL22531823 | 0.82 | MLYCD (0.57) | MLYCDTPMTCA1CA2ALDH1A1 | |
| SCHEMBL1303906 | 0.82 | MLYCD (0.57) | MLYCDCA1CA2ALDH1A1HPGD | |
| SCHEMBL6616024 | 0.80 | MLYCD (0.56) | MLYCDCA1CA2ALDH1A1HPGD | |
| SCHEMBL286256 | 0.80 | CES2 (0.57) | MLYCDCA1CA2ALDH1A1HPGD | |
| SCHEMBL3305455 | 0.80 | ALDH1A1 (0.57) | MLYCDALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL623946 | 0.80 | PKM (0.56) | MLYCDCA1CA2ALDH1A1HPGD | |
| SCHEMBL306600 | 0.80 | MLYCD (0.60) | MLYCDCA1CA2ALDH1A1HPGD | |
| SCHEMBL1765450 | 0.80 | MLYCD (0.56) | MLYCDCA1CA2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678632-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | AGC Inc. (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20250346557-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | AGC Inc. (JP) | 2025-11-13 | — | — | US | disclosed |
| WO-2024185814-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | ＡＧＣ株式会社 | 2024-09-12 | — | — | WO | disclosed |
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024008909-A1 | INHIBITORS OF CORONAVIRUS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-11 | — | — | WO | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230271971-A1 | CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKING | BLUEPRINT MEDICINES CORPORATION | 2023-08-31 | — | — | US | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11542233-B2 | Compounds, compositions and methods of use | AQUINNAH PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2002024683-A1 | FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
| EP-0796858-B1 | Triazole antifungal agents | PFIZER LTD (GB) | 2000-11-02 | — | — | EP | disclosed |
| US-6124325-A | Triazole antifungal agents | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6015825-A | Triazole antifungal agents | PFIZER INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5981560-A | 1,2,4-TRIAZOLE FUNGICIDES | PFIZER INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0880533-A1 | TRIAZOLE DERIVATIVES USEFUL IN THERAPY | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-12-02 | — | — | EP | disclosed |
| EP-0835252-A1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-04-15 | — | — | EP | disclosed |
| EP-0796858-A1 | Triazole antifungal agents | Pfizer Limited (GB) | 1997-09-24 | — | — | EP | disclosed |
| WO-1997028169-A1 | TRIAZOLE DERIVATIVES USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997001552-A1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542233-B2 | Compounds, compositions and methods of use | FUS, TFEB, CLN6 | MLYCD 2474/4885TPMT 2881/4885CA1 4206/4885 |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | MLYCD 2474/4885TPMT 2881/4885CA1 4206/4885 |
| US-20230271971-A1 | CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKING | PDGFRA, KIT, PDGFRB | MLYCD 4005/4885TPMT 991/4885CA1 3173/4885 |
| US-20250346557-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | STS, TST, CYP3A5 | MLYCD 4297/4885TPMT 195/4885CA1 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.